Article
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Cancer - 1 Jun 2018
Hirsch Fred R, Sequist Lecia V, Gore Ira, Mooradian Meghan, Simon George, Croft Elisabeth F, DeVincenzo Diana, Munley Jiefen, Stein Dara, Freivogel Klaus, Sifakis Frangiscos, Bunn Paul A
Abstract excerpt
BACKGROUND: This is the first report of long-term (>10 years) safety, tolerability, and survival data on patients with non-small cell lung cancer (NSCLC) who received treatment with gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. METHODS: Patients with advanced NSCLC (N = 191) who entered the IRESSA Clinical Access Program (ICAP) (June 2011 to January 2013) and had previously...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.